Cipla
GenericsCipla is a generic drug manufacturer focused on Infectious Disease, Oncology, Immunology. Key products include ZEMDRI.
Cipla's Key Drugs
Cipla's core commercial portfolio centers on FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, LOPINAVIR AND RITONAVIR, EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, spanning Infectious Disease and Oncology — its most strategically important drugs approved in the last 15 years.
Hay Fever
HIV Infection
HIV-1 infection
Hypophosphatemia
Cipla's Recent FDA Approvals
Cipla secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Cipla's Therapeutic Areas
Cipla's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Oncology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Cipla's Top Competitors
Cipla's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Cipla Pipeline Snapshot
Cipla has 4 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (3)
Company Info
- First Approval
- 2001-09-19
- Latest
- 2026-08-31
- Applications
- 170